Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
BNF presentation directory
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Navelbine 50mg/5ml concentrate for inf vials
0801040R0BBABAB
|
Navelbine | Vinorelbine | Malignant Disease and Immunosuppression | No data available |
|
Navelbine 80mg capsules
0801040R0BBAEAE
|
Navelbine | Vinorelbine | Malignant Disease and Immunosuppression | No data available |
|
Nelarabine 250mg/50ml solution for infusion vials
0801030ABAAAAAA
|
Nelarabine | Nelarabine | Malignant Disease and Immunosuppression | No data available |
|
Nexavar 200mg tablets
0801050AJBBAAAA
|
Nexavar | Sorafenib | Malignant Disease and Immunosuppression | No data available |
|
Nibix 100mg capsules
0801050AABCAAAA
|
Nibix | Imatinib mesilate | Malignant Disease and Immunosuppression | No data available |
|
Nibix 400mg capsules
0801050AABCABAD
|
Nibix | Imatinib mesilate | Malignant Disease and Immunosuppression | No data available |
|
Nilotinib 150mg capsules
0801050ASAAABAB
|
Nilotinib | Nilotinib | Malignant Disease and Immunosuppression | No data available |
|
Nilotinib 50mg capsules
0801050ASAAACAC
|
Nilotinib | Nilotinib | Malignant Disease and Immunosuppression | No data available |
|
Ninlaro 2.3mg capsules
0801050CCBBAAAA
|
Ninlaro | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Ninlaro 3mg capsules
0801050CCBBABAB
|
Ninlaro | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Ninlaro 4mg capsules
0801050CCBBACAC
|
Ninlaro | Ixazomib | Malignant Disease and Immunosuppression | No data available |
|
Nintedanib 150mg capsules
0801050BTAAABAB
|
Nintedanib | Nintedanib | Malignant Disease and Immunosuppression | No data available |
|
Nipent 10mg powder for solution for injection vials
0801050S0BBAAAA
|
Nipent | Pentostatin | Malignant Disease and Immunosuppression | No data available |
|
Niraparib 100mg capsules
0801050CJAAAAAA
|
Niraparib | Niraparib | Malignant Disease and Immunosuppression | No data available |
|
Nivolumab 100mg/10ml solution for infusion vials
0802040ATAAABAB
|
Nivolumab (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Nivolumab 240mg/24ml solution for infusion vials
0802040ATAAACAC
|
Nivolumab (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Nivolumab 40mg/4ml solution for infusion vials
0802040ATAAAAAA
|
Nivolumab (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Nivolumab BMS 100mg/10ml concentrate for inf vials
0802040ATBCAAAB
|
Nivolumab BMS (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Nivolumab BMS 40mg/4ml concentrate for inf vials
0802040ATBCABAA
|
Nivolumab BMS (old) | Nivolumab (old) | Malignant Disease and Immunosuppression | No data available |
|
Nolvadex 10mg tablets
0803041S0BCAAAA
|
Nolvadex | Tamoxifen citrate | Malignant Disease and Immunosuppression | No data available |
|
Novantrone 20mg/10ml solution for infusion vials
0801020R0BBAAAA
|
Novantrone | Mitoxantrone | Malignant Disease and Immunosuppression | No data available |
|
Novantrone 25mg/12.5ml solution for infusion vials
0801020R0BBABAB
|
Novantrone | Mitoxantrone | Malignant Disease and Immunosuppression | No data available |
|
Novantrone 30mg/15ml solution for infusion vials
0801020R0BBACAC
|
Novantrone | Mitoxantrone | Malignant Disease and Immunosuppression | No data available |
|
Novgos 3.6mg implant pre-filled syringes
0803042K0BCAAAA
|
Novgos | Goserelin acetate | Malignant Disease and Immunosuppression | No data available |
|
Nulojix 250mg pdr for concentrate for inf vials
0802020Y0BBAAAA
|
Nulojix | Belatacept | Malignant Disease and Immunosuppression | No data available |
Why monitor BNF codes?
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Understand demand drivers
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.